COGT
Cogent Biosciences, Inc.
$39.97
-0.04 (-0.10%)
At close · Jul 8
Market Cap
$6.95B
Shares
170,868,004
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$7.87M
0%
FY2021
Net Income
-$328.94M
-28.6%
FY2025
Operating Margin
-959.87%
+84.5pp
FY2021
Diluted EPS
-$2.16
-11.3%
FY2025
Operating Cash Flow
-$264.44M
-27.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | $7.87M | $7.87M | $22.5M | $9.73M | |
| $282.12M | $269.78M | $232.66M | $173.76M | $121.63M | $55.91M | $25.74M | $43.71M | $38.29M | |
| $79.92M | $63.58M | $43.28M | $34.38M | $26.21M | $19.64M | $17.42M | $10.97M | $7.45M | |
| — | $2.6M | $2.5M | $2.27M | $842K | $147K | $720K | $1.29M | $1.32M | |
| — | — | — | — | — | — | $4.17M | — | — | |
| $362.04M | $333.36M | $275.94M | $208.13M | $147.84M | $75.55M | $90.07M | $54.68M | $45.74M | |
| -$362.04M | -$333.36M | -$275.94M | -$208.13M | -$147.84M | -$75.55M | -$82.2M | -$32.18M | -$36.01M | |
| — | — | — | — | — | -959.87% | -1044.33% | -143.02% | -369.89% | |
| — | -$330.76M | -$273.44M | -$205.86M | -$147M | -$75.4M | -$81.48M | -$30.89M | -$34.68M | |
| — | $3.06M | — | — | — | — | — | — | — | |
| $19.35M | $14.69M | $18.09M | $13.08M | $3.99M | $467K | $144K | $267K | $1.15M | |
| $7.73M | $4.43M | $20.08M | $15.72M | $7.6M | $3.28M | $7.39M | $345K | $1.47M | |
| — | $0 | — | — | — | — | — | — | — | |
| -$354.3M | -$328.94M | -$255.86M | -$192.41M | -$140.24M | -$72.27M | -$74.81M | -$31.83M | -$34.53M | |
| — | — | — | — | — | -918.22% | -950.43% | -141.49% | -354.76% | |
| -$242.3M | — | — | -$192.41M | -$140.24M | -$72.27M | -$179.21M | -$31.83M | -$34.55M | |
| -$354.88M | -$329.03M | -$255.66M | -$192.06M | -$140.35M | — | -$74.81M | -$31.82M | -$34.53M | |
| USD/shares | — | -$2.16 | -$1.94 | -$2.42 | -$2.39 | — | — | $0.28 | — |
| USD/shares | — | -$2.16 | -$1.94 | -$2.42 | -$2.39 | — | — | $0.28 | — |
| shares | — | 128.9M | 103.86M | 79.66M | 58.74M | 38.73M | 11.08M | 7.62M | 6.22M |
| shares | — | 128.9M | 103.86M | 79.66M | 58.74M | 38.73M | 11.08M | 7.62M | 6.22M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Latestage Development | $120,059,000 | $120,862,000 | $85,484,000 | $61,270,000 |
| Research and Development Personnel Related | $64,035,000 | $47,048,000 | $38,206,000 | $26,421,000 |
| Stock-Based Compensation Expense | $46,079,000 | $39,740,000 | $30,621,000 | $18,367,000 |
| Other Operational Infrastructure and Advisory Support | $40,429,000 | $26,886,000 | $23,010,000 | $21,605,000 |
| Early Stage Preclinical and Discovery Programs | $40,112,000 | $28,141,000 | $19,171,000 | $12,957,000 |
| Research And Development Software Facilities And Other Strategic Support | $20,085,000 | $10,812,000 | $9,374,000 | $6,377,000 |
| Depreciation Expense | $2,564,000 | $2,450,000 | $2,264,000 | $842,000 |